950 Winter Street
About Radius HealthRadius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.
Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.
October 3, 2003
Founders: John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts
CEO: Robert Ward
CMO (Medical): Lorraine Fitzpatrick
CFO: Nick Harvey
CSO (Scientific): Gary Hattersley
Please click here for Radius Health job opportunities.
Please click here for clinical trial information.
190 articles with Radius Health
Radius Health Announces Proposed Public Offering Of $300 Million Of Convertible Senior Notes Due 2024
Radius Health Reports Second Quarter 2017 Financial And Operating Results And Provides Business Update
Radius Health Announces License And Development Agreement For Abaloparatide-SC With Teijin Limited In Japan
Radius Health To Announce Second Quarter 2017 Financial Results, Host Conference Call And Live Webcast On August 3, 2017
Radius Health Presents Positive Data From A Fully Enrolled Ongoing Phase I Study For Investigational Drug Elacestrant (RAD1901) At The 2017 ASCO
FDA Approves Radius Health’s TYMLOS (Abaloparatide), A Bone Building Agent For The Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture
Radius Health Announces Presentations At Upcoming Conferences And Its Plans To Announce First Quarter Financial Results On May 3, 2017
Radius Health Release: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies
Radius Health Release: Mayo Clinic Proceedings Publishes Positive Results From The Activextend Clinical Trial Of Abaloparatide-SC In Postmenopausal Women With Osteoporosis
Radius Health To Announce Fourth Quarter And Full Year 2016 Financial Results, Host Conference Call And Live Webcast On February 23, 2017
Radius Health Presents Positive Phase I Data For Investigational Drug RAD1901 At The San Antonio Breast Cancer Symposium (SABCS) 2016